{
  "RUBI_protocole_v8-0_20210519_signe": {
    "NOAEL": "No-observed-adverse-effect-level",
    "OCT": "Optical coherence tomography",
    "OUD": "Occurrence of uveitic disease",
    "PBMC": "Peripheral blood mononuclear cell",
    "PD": "Pharmacodynamic",
    "PK": "Pharmacokinetic",
    "PO": "Oxygen pressure",
    "PPD": "Purified protein derivative",
    "Q4W": "Every 4 weeks",
    "QOL": "Quality of life",
    "RA": "Rheumatoid arthritis",
    "SAE": "Serious adverse event",
    "SC": "Subcutaneous",
    "SPR": "Surface Plasmon Resonance",
    "SUN": "Standardization of Uveitis Nomenclature",
    "TB": "Tuberculosis",
    "TBD": "To be determined",
    "TH1": "T helper 1 cell",
    "TH17": "T helper 17 cell",
    "TLR": "Toll-like receptor",
    "T2D": "Type 2 diabetes",
    "ULN": "Upper limit of normal",
    "WBC": "White blood cell (count)",
    "WHODD": "World Health Organization Drug",
    "WMA": "World Medical Association"
  }
}